Medicinal chemistry of hERG optimizations: Highlights and hang-ups

被引：363

作者：

Jamieson, Craig ^{[1
]}

Moir, Elizabeth M. ^{[1
]}

Rankovic, Zoran ^{[1
]}

Wishart, Grant ^{[1
]}

机构：

[1] Organon Res Labs Ltd, Med Chem, Newhouse ML1 5SH, Lanark, Scotland

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2006年 / 49卷 / 17期

关键词：

D O I：

10.1021/jm060379l

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

[No abstract available]

引用

页码：5029 / 5046

页数：18

共 71 条

[1] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia [J].

Abbott, GW ;

Sesti, F ;

Splawski, I ;

Buck, ME ;

Lehmann, WH ;

Timothy, KW ;

Keating, MT ;

Goldstein, SAN .

CELL, 1999, 97 (02) :175-187

[2] Tetrahydronaphthalene-derived amino alcohols and amino ketones as potent and selective inhibitors of the delayed rectifier potassium current IKs [J].

Ahmad, S ;

Doweyko, L ;

Ashfaq, A ;

Ferrara, FN ;

Bisaha, SN ;

Schmidt, JB ;

DiMarco, J ;

Conder, ML ;

Jenkins-West, T ;

Normandin, DE ;

Russell, AD ;

Smith, MA ;

Levesque, PC ;

Lodge, NJ ;

Lloyd, J ;

Stein, PD ;

Atwal, KS .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) :99-102

[3] Prediction of herg K+ blocking potency:: Application of structural knowledge [J].

Aptula, AO ;

Cronin, MTD .

SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2004, 15 (5-6) :399-411

[4] A model for identifying HERG K+ channel blockers [J].

Aronov, AM ;

Goldman, BB .

BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (09) :2307-2315

[5] Predictive in silico modeling for hERG channelblockers [J].

Aronov, MM .

DRUG DISCOVERY TODAY, 2005, 10 (02) :149-155

[6] HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study [J].

Bains, W ;

Basman, A ;

White, C .

PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2004, 86 (02) :205-233

[7] 3-aminopyrrolidinone farnesyltransferase inhibitors: Design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency [J].

Bell, IM ;

Gallicchio, SN ;

Abrams, M ;

Beese, LS ;

Beshore, DC ;

Bhimnathwala, H ;

Bogusky, MJ ;

Buser, CA ;

Culberson, JC ;

Davide, J ;

Ellis-Hutchings, M ;

Fernandes, C ;

Gibbs, JB ;

Graham, SL ;

Hamilton, KA ;

Hartman, GD ;

Heimbrook, DC ;

Homnick, CF ;

Huber, HE ;

Huff, JR ;

Kassahun, K ;

Koblan, KS ;

Kohl, NE ;

Lobell, RB ;

Lynch, JJ ;

Robinson, R ;

Rodrigues, AD ;

Taylor, JS ;

Walsh, ES ;

Williams, TM ;

Zartman, CB .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (12) :2388-2409

[8] Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency [J].

Bell, IM ;

Gallicchio, SN ;

Abrams, M ;

Beshore, DC ;

Buser, CA ;

Culberson, JC ;

Davide, J ;

Ellis-Hutchings, M ;

Fernandes, C ;

Gibbs, JB ;

Graham, SL ;

Hartman, GD ;

Heimbrook, DC ;

Homnick, CF ;

Huff, JR ;

Kassahun, K ;

Koblan, KS ;

Kohl, NE ;

Lobell, RB ;

Lynch, JJ ;

Miller, PA ;

Omer, CA ;

Rodrigues, AD ;

Walsh, ES ;

Williams, TM .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (18) :2933-2949

[9] Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel [J].

Bilodeau, MT ;

Balitza, AE ;

Koester, TJ ;

Manley, PJ ;

Rodman, LD ;

Buser-Doepner, C ;

Coll, KE ;

Fernandes, C ;

Gibbs, JB ;

Heimbrook, DC ;

Huckel, WR ;

Kohl, N ;

Lynch, JJ ;

Mao, XZ ;

McFall, RC ;

McLoughlin, D ;

Miller-Stein, CM ;

Rickert, KW ;

Sepp-Lorenzino, L ;

Shipman, JM ;

Subramanian, R ;

Thomas, KA ;

Wong, BK ;

Yu, S ;

Hartman, GD .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (25) :6363-6372

[10]

*BIOB CORP, CLOGP VERS 4 10

← 1 2 3 4 5 6 7 8 →